METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

March 13, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Ovarian Cancer
Interventions
DRUG

METR-NK cells combined with Solvatinib

"Sorafenib 250mg po qd, 3 weeks as a course, a total of 3 courses, the drug was stopped 3 weeks before cytoreduction of intermediate tumor.~Dilute METR - 200 mL of NK cells in 37 ℃ 1500 mL of 0.9% sodium chloride physiological saline, intraperitoneal infusion, flow rate \> 150 drops/min, each METR - venous back to the throughput of NK cells is lower than 2 x 107 cells/kg, abdominal cavity to throughput of no less than 4 x 107 cells/kg, Three days of continuous infusion was taken as a course of treatment, and four courses of continuous infusion (the first course of infusion did not use METR-NK cells) were given, with an interval of 14 days for each course. The position was switched every 15 min after the completion of each infusion to ensure uniform distribution of cells to the tumor surface."

Trial Locations (1)

230001

Anhui Cancer Hospitail, Hefei

All Listed Sponsors
lead

Anhui Provincial Cancer Hospital

OTHER

NCT06884345 - METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter